Aqueous formulations suitable for intranasal administration comprise buprenorphine or a physiologically acceptable salt or ester thereof and (a) a pectin having a degree of esterification of less than 50%, (b) chitosan and a polyoxyethylene-poly-oxypropylene copolymer (poloxamer) or (c) chitosan and hydroxypropylmethylcellulose. Such formulations can induce rapid and prolonged analgesia when delivered…
Buprenorphine formulations for intranasal delivery
Call 1 (888) 460-6556 to speak with a counselor.
Previous post: Transmucosal delivery devices with enhanced uptake
Next post: Processes for synthesis of opiate alkaloid derivatives
